fadfebrian
Clinical-stage biotech Aktis Oncology (AKTS), which counts Eli Lilly (LLY) among its partners, traded sharply higher after the cancer drug developer made its public debut on Nasdaq on Friday following an upsized initial public offering.
After pricing the IPO at $18.00